Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

被引:132
|
作者
Baptista, Marco A. S. [1 ]
Dave, Kuldip D. [1 ]
Frasier, Mark A. [1 ]
Sherer, Todd B. [1 ]
Greeley, Melanie [2 ]
Beck, Melissa J. [2 ]
Varsho, Julie S. [2 ]
Parker, George A. [2 ]
Moore, Cindy [3 ,4 ]
Churchill, Madeline J. [3 ,4 ]
Meshul, Charles K. [3 ,4 ]
Fiske, Brian K. [1 ]
机构
[1] Michael J Fox Fdn Parkinsons Res, Res Programs, New York, NY USA
[2] WIL Res, Ashland, OH USA
[3] Oregon Hlth & Sci Univ, VA Med Ctr Portland, Res Serv, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA
来源
PLOS ONE | 2013年 / 8卷 / 11期
关键词
PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; IMPAIRMENT; MUTATIONS; G2019S;
D O I
10.1371/journal.pone.0080705
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-months of age. The evaluation consisted of histopathology and ultrastructure examination of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematology, serum, and urine analysis. The LRRK2 knockout rat, starting at 2-months of age, displayed abnormal kidney staining patterns and/or morphologic changes that were associated with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat. Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine specific gravity, total volume, urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-months of age. Electron microscopy of 16-month old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype. In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats. These findings partially replicate data from a recent study in 4-month old LRRK2 knockout rats [1] and expand the analysis to demonstrate that the renal and possibly lung and liver abnormalities progress with age. The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.
引用
收藏
页数:16
相关论文
共 50 条
  • [11] Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
    Smith, WW
    Pei, Z
    Jiang, HB
    Moore, DJ
    Liang, YD
    West, AB
    Dawson, VL
    Dawson, TM
    Ross, CA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) : 18676 - 18681
  • [12] The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2)
    Konstantinidou, Markella
    Oun, Asmaa
    Pathak, Pragya
    Zhang, Bidong
    Wang, Zefeng
    ter Brake, Frans
    Dolga, Amalia M.
    Kortholt, Arjan
    Domling, Alexander
    CHEMMEDCHEM, 2021, 16 (06) : 959 - 965
  • [13] Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Greshock, Thomas J.
    Sanders, John M.
    Drolet, Robert E.
    Rajapakse, Hemaka A.
    Chang, Ronald K.
    Kim, Boyoung
    Rada, Vanessa L.
    Tiscia, Heather E.
    Su, Hua
    Lai, Ming-Tain
    Sur, Sylvie M.
    Sanchez, Rosa I.
    Bilodeau, Mark T.
    Renger, John J.
    Kern, Jonathan T.
    McCauley, John A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (11) : 2631 - 2635
  • [14] Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
    Pungaliya, Pooja P.
    Bai, Yuchen
    Lipinski, Kerri
    Anand, Vasanti S.
    Sen, Saurabh
    Brown, Eugene L.
    Bates, Brian
    Reinhart, Peter H.
    West, Andrew B.
    Hirst, Warren D.
    Braithwaite, Steven P.
    PLOS ONE, 2010, 5 (10):
  • [15] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [16] Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity
    Nikonova, Elena V.
    Xiong, Yulan
    Tanis, Keith Q.
    Dawson, Valina L.
    Vogel, Robert L.
    Finney, Eva M.
    Stone, David J.
    Reynolds, Ian J.
    Kern, Jonathan T.
    Dawson, Ted M.
    HUMAN MOLECULAR GENETICS, 2012, 21 (01) : 163 - 174
  • [17] Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
    Fernandez, Belen
    Chittoor-Vinod, Vinita G.
    Kluss, Jillian H.
    Kelly, Kaela
    Bryant, Nicole
    Nguyen, An Phu Tran
    Bukhari, Syed A.
    Smith, Nathan
    Ordonez, Antonio Jesus Lara
    Fdez, Elena
    Chartier-Harlin, Marie-Christine
    Montine, Thomas J.
    Wilson, Mark A.
    Moore, Darren J.
    West, Andrew B.
    Cookson, Mark R.
    Nichols, R. Jeremy
    Hilfiker, Sabine
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (05) : 1423 - 1447
  • [18] Differential Effects of Divalent Manganese and Magnesium on the Kinase Activity of Leucine-Rich Repeat Kinase 2 (LRRK2)
    Lovitt, Brian
    VanderPorten, Erica C.
    Sheng, Zejuan
    Zhu, Haitao
    Drummond, Jake
    Liu, Yichin
    BIOCHEMISTRY, 2010, 49 (14) : 3092 - 3100
  • [19] Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond
    Bae, Jae Ryul
    Lee, Byoung Dae
    BMB REPORTS, 2015, 48 (05) : 243 - 248
  • [20] Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian
    Belin, Andrea Carmine
    Westerlund, Marie
    Sydow, Olof
    Lundstromer, Karin
    Hakansson, Anna
    Nissbrandt, Hans
    Olson, Lars
    Galter, Dagmar
    MOVEMENT DISORDERS, 2006, 21 (10) : 1731 - 1734